Drug Trial Radar · NCT03841448
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Last checked: Nov 20, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
31
Actual
Start
Sep 30, 2019
Primary completion
Mar 17, 2022
Study completion Jun 27, 2023
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete \>1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.
Conditions
- IgA Nephropathy (IgAN)
- Berger Disease
- Glomerulonephritis, IgA
Interventions
PlaceboDrug
Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
CemdisiranDrug
Cemdisiran was administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in UPCR as Measured in 24-hour Urine at Week 32Time frame: Baseline to Week 32
Locations
17 sites in 9 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Vancouver, British Columbia, Canada
Clinical Trial Site
Brampton, Ontario, Canada
Clinical Trial Site
Toronto, Ontario, Canada
Clinical Trial Site
Grenoble, France
Clinical Trial Site
La Tronche, France
Clinical Trial Site
Mulhouse, France
Clinical Trial Site
Kuala Lumpur, Malaysia
Clinical Trial Site
Kuantan, Malaysia
Clinical Trial Site
Serdang, Malaysia
Clinical Trial Site
Quezon City, Philippines
Clinical Trial Site
Singapore, Singapore
Clinical Trial Site
Córdoba, Spain
Clinical Trial Site
Girona, Spain
Clinical Trial Site
Huddinge, Sweden
Clinical Trial Site
Uppsala, Sweden
Clinical Trial Site
Taichung, Taiwan
Clinical Trial Site
Leicester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.